Drug intelligence / Profile preview

BNT24005

Development stage: Preclinical
Lead developer: BioNxt Solutions
Modality: Small Molecules
Administration: Sublingual

Overview

BNT24005 is a preclinical drug candidate developed by BioNxt Solutions (formerly XPhyto Therapeutics) for the prevention of rejection in solid organ transplantation. It utilizes a sublingual oral dissolving film (ODF) delivery platform to administer an undisclosed small molecule mTOR inhibitor. By inhibiting the mechanistic target of rapamycin (mTOR), the drug aims to provide immunosuppression, which is critical for transplant recipients to prevent the immune system from attacking the donor organ. The ODF formulation is designed to improve patient compliance and potentially enhance bioavailability by allowing for rapid absorption through the sublingual mucosa, bypassing first-pass metabolism in the liver.

Other names: mTOR inhibitor ODF

Targets

mTOR (Mammalian target of rapamycin kinase)

Beyond the preview

Go deeper on BNT24005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BNT24005.

Explore the full profile